Literature DB >> 23613254

X-linked reticulate pigmentary disorder with systemic manifestations: a new family and review of the literature.

Lidia Pezzani1, Michela Brena, Michele Callea, Marina Colombi, Gianluca Tadini.   

Abstract

X-linked reticulate pigmentation disorder with systemic manifestations (XLPDR) is an extremely rare genodermatosis with recessive X-linked inheritance but unknown molecular basis. In males, cutaneous involvement is characterized by reticulate hyperpigmentation of the skin that is associated with a typical facies and severe systemic involvement. In the carrier females, manifestations are apparently limited to the skin with patchy linear hyperpigmentation following the lines of Blaschko that are similar to stage III incontinentia pigmenti. Thus far, only five families affected by this disorder have been described. We report on a new family with clinical features of XLPDR and compare it with those reported in the literature.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23613254     DOI: 10.1002/ajmg.a.35882

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Evolution of the skin manifestations of X-linked pigmentary reticulate disorder.

Authors:  P Starokadomskyy; L Sifuentes-Dominguez; T Gemelli; A R Zinn; M T Dossi; C Mellado; P Bertrand; A Borzutzky; E Burstein
Journal:  Br J Dermatol       Date:  2017-10-08       Impact factor: 9.302

2.  X-linked reticulate pigmentary disorder in a 4-year-old boy.

Authors:  Yu-Kun Zhao; Li-Hua Fan; Jing-Fa Lu; Ze-Yu Luo; Zhi-Miao Lin; Hui-Jun Wang; Di-Qing Luo
Journal:  Postepy Dermatol Alergol       Date:  2022-05-09       Impact factor: 1.664

3.  DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis.

Authors:  Petro Starokadomskyy; Terry Gemelli; Jonathan J Rios; Chao Xing; Richard C Wang; Haiying Li; Vladislav Pokatayev; Igor Dozmorov; Shaheen Khan; Naoteru Miyata; Guadalupe Fraile; Prithvi Raj; Zhe Xu; Zigang Xu; Lin Ma; Zhimiao Lin; Huijun Wang; Yong Yang; Dan Ben-Amitai; Naama Orenstein; Huda Mussaffi; Eulalia Baselga; Gianluca Tadini; Eyal Grunebaum; Adrijan Sarajlija; Konrad Krzewski; Edward K Wakeland; Nan Yan; Maria Teresa de la Morena; Andrew R Zinn; Ezra Burstein
Journal:  Nat Immunol       Date:  2016-03-28       Impact factor: 25.606

Review 4.  JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?

Authors:  S A Kerrigan; I B McInnes
Journal:  Curr Rheumatol Rep       Date:  2018-11-08       Impact factor: 4.592

Review 5.  Congenital Diseases of DNA Replication: Clinical Phenotypes and Molecular Mechanisms.

Authors:  Megan Schmit; Anja-Katrin Bielinsky
Journal:  Int J Mol Sci       Date:  2021-01-18       Impact factor: 5.923

Review 6.  Immune Dysfunction in Mendelian Disorders of POLA1 Deficiency.

Authors:  Petro Starokadomskyy; Andrea Escala Perez-Reyes; Ezra Burstein
Journal:  J Clin Immunol       Date:  2021-01-03       Impact factor: 8.542

7.  NK cell defects in X-linked pigmentary reticulate disorder.

Authors:  Petro Starokadomskyy; Katelynn M Wilton; Konrad Krzewski; Adam Lopez; Luis Sifuentes-Dominguez; Brittany Overlee; Qing Chen; Ann Ray; Aleksandra Gil-Krzewska; Mary Peterson; Lisa N Kinch; Luis Rohena; Eyal Grunebaum; Andrew R Zinn; Nick V Grishin; Daniel D Billadeau; Ezra Burstein
Journal:  JCI Insight       Date:  2019-11-01

8.  JAK Inhibition in a Patient with X-Linked Reticulate Pigmentary Disorder.

Authors:  Corinne Légeret; Benedikt J Meyer; Annette Rovina; Nikolaus Deigendesch; Christoph T Berger; Thomas Daikeler; Ingmar Heijnen; Ezra Burstein; Henrik Köhler; Mike Recher
Journal:  J Clin Immunol       Date:  2020-09-28       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.